The biotech M&A market was exceptionally strong in 2025, a trend driven by the strategic necessity for large pharmaceutical companies to acquire new assets to counteract looming patent expirations.
The U.S. Food and Drug Administration (FDA) is in a state of 'chaos and dysfunction,' which poses a significant and growing risk of major operational stumbles for the industry in 2026.
The obesity drug market is the single most important driver of value and strategic activity in biotech, exemplified by Eli Lilly's $1 trillion valuation and Pfizer's $10B+ acquisition of MetSara.
Despite persistent political rhetoric and some concessions, concerns over drug pricing did not materially harm the financial results of most biotech and pharmaceutical companies in 2025.
He is willing to be highly critical of specific corporate leadership and clinical outcomes, naming Sarepta's CEO as the worst of 2025 and highlighting the acute liver failure deaths in its trials.
Early April 2025
Feuerstein reports that the XBI biotech index was down 22% year-to-date, indicating a weak start for the sector.
2025
Eli Lilly becomes the first healthcare company to achieve a $1 trillion market valuation, a major highlight of the year.
2025
A bidding war between Pfizer and Novo Nordisk for obesity drug developer MetSara concludes with a deal price exceeding $10 billion, highlighting intense M&A activity.
2025
Feuerstein characterizes 2025 as the strongest year for biotech M&A since 2019, driven by large pharma's need to acquire assets due to patent expirations.
Late 2025
The XBI biotech index rebounds significantly, finishing the year up 37%.
Year-End 2025
Feuerstein expresses growing concern over dysfunction at the FDA and potential NIH funding cuts, while also naming Sarepta's CEO as the worst of the year.
▶The M&A ResurgenceApr 2026
Feuerstein identifies 2025 as the strongest year for biotech mergers and acquisitions since 2019. This activity is primarily driven by large pharmaceutical companies facing patent expirations and loss of exclusivity, forcing them to acquire new assets like the obesity drug pipeline from MetSara in a deal exceeding $10 billion.
Investors should closely monitor small-to-mid-cap biotech firms with promising clinical data in high-demand areas, as they are prime acquisition targets for industry giants seeking to replenish their pipelines.
▶The Obesity Drug Gold RushApr 2026
The market for obesity treatments, particularly GLP-1 drugs, is a central driver of industry dynamics and valuations. This is evidenced by Eli Lilly becoming the first healthcare company to reach a $1 trillion valuation and Pfizer's massive acquisition of MetSara, which was contested by Novo Nordisk.
Future growth for major pharmaceutical companies like Pfizer is now heavily dependent on success in the obesity space, making clinical trial data and market positioning in this specific category a critical factor for analysis.
▶Looming Regulatory and Political Risk
Feuerstein expresses significant concern about the U.S. Food and Drug Administration (FDA), describing it as being in a state of 'chaos and dysfunction.' He also worries that potential deep cuts to NIH research funding under the Trump administration will negatively impact long-term innovation.
Analysts must factor in heightened regulatory risk for 2026, as potential FDA operational stumbles could create unexpected delays and headwinds for companies awaiting key drug approvals.
▶A Market of Extreme Winners and Losers
The 2025 biotech sector was characterized by sharply contrasting outcomes. While Eli Lilly achieved a landmark valuation and the XBI index recovered strongly, the year also saw high-profile clinical setbacks (Uniqure, Replimune), leadership criticism (Sarepta's CEO), and company shutdowns (Third Harmonic Bio).
The high-risk, high-reward nature of biotech investing is intensifying, suggesting that broad market index performance can be misleading and that deep diligence into specific companies, their leadership, and clinical data is more critical than ever.